黄芪多糖通过减轻免疫炎症抑制病毒性肝炎小鼠肝损伤OA北大核心CSTPCD
Astragalus polysaccharide inhibits liver injury in mice with viral hepatitis by reducing immune inflammation
目的:观察黄芪多糖对病毒性肝炎小鼠肝损伤的影响,并探讨其是否能通过调控核苷酸结合寡聚化结构域1(NOD1)/受体相互作用蛋白2(RIP2)/核转录因子-κB(NF-κB)通路介导的免疫炎症发挥肝保护作用.方法:将60只雌性C3H/HeJ小鼠,采用随机数字表法分为建模组(50只)和正常组(10只).建模组采用3型鼠肝炎病毒(MHV-3)腹腔注射建立病毒性肝炎小鼠模型,并于确定建模成功后将存活小鼠采用随机数字表法分为胸腺肽组(10 µg)、黄芪多糖低、中、高剂量组(腹腔注射100、200、400 mg/kg黄芪多糖冻干溶于1 ml/100 g体质量的生理盐水)、模型组.模型组和正常组予以等量生理盐水腹腔注射,各组均每天给药1次,连续1个月.结果:经肝组织苏木素-伊红(HE)染色和病毒空斑数检测证实建模成功;与正常组比较,模型组小鼠肝脏指数,血清谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBIL)、肿瘤坏死因子-α(TNF-α)、IL-1β、IL-8水平,肝组织病毒空斑数,肝组织NOD1、RIP2、NF-κB p65表达与p-NF-κB p65水平均升高(P<0.05),肝组织呈严重病理改变;与模型组小鼠比较,胸腺肽组和黄芪多糖各剂量组肝脏指数,血清ALT、AST、TBIL、TNF-α、IL-1β、IL-8水平,肝组织病毒空斑数,肝组织NOD1、RIP2、NF-κB p65表达与p-NF-κB p65水平均下降(P<0.05),肝组织病理改变均减轻,且黄芪多糖的作用呈剂量依赖性,胸腺肽组与黄芪多糖中剂量组比较上述指标差异均无统计学意义(P>0.05).结论:黄芪多糖可改善病毒性肝炎小鼠的肝功能,减轻炎症反应和肝组织病理改变,降低病毒水平,推测与抑制NOD1/RIP2/NF-κB通路,下调NOD1、RIP2、NF-κB p65 mRNA与蛋白表达,抑制NF-κB p65磷酸化有关,且高剂量的黄芪多糖效果最佳,并优于胸腺肽-α1.
Objective:To observe the effect of astragalus polysaccharides on liver injury in mice with viral hepatitis,and to investigate whether it can regulate the expression of nucleotide-binding oligomerization domain 1(NOD1)/receptor-interacting protein 2(RIP2)/nuclear factor-κB(NF-κB)immune inflammation mediated by signaling pathway plays a protective role in liver.Methods:Sixty female C3H/HeJ mice were divided into modeling group(50 mice)and normal group(10 mice)using a random number table.The mouse model of viral hepatitis was established by intraperitoneal injection of mouse hepatitis virus type 3(MHV-3)in the modeling group.After the successful modeling was confirmed,the surviving mice were divided into thymus peptide group(10 µg),astragalus polysaccharide low,medium and high dose groups(100,200,400 mg/kg astragalus polysaccharide lyophilized in 1 ml/100 g body weight saline)and model group by random number table.Model group and normal group were given the same amount of normal saline intraperitoneal injection,each group was given once a day for 1 month.Results:The model was confirmed by HE staining of liver tis-sue and detection of viral plaque.Compared with the normal group,the liver index,serum alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bilirubin(TBIL)and tumor necrosis factor-α(TNF-α),IL-1β and IL-8,viral plaques in liver tissue,NOD1,RIP2 and NF-κB p65 expressions and p-NF-κB p65 level in the model group increased(P<0.05),and the liver tissue showed severe pathological changes.Compared with the model group,the liver indexes,serum ALT,AST,TBIL and TNF-α,IL-1β and IL-8,viral plaques in liver tissue,NOD1,RIP2 and NF-κB p65 expressions and p-NF-κB p65 level in the thymosin group and astragalus polysaccharide each 3-dose groups decreased(P<0.05),and the pathological changes of liver tissue were alleviated.The effect of astragalus polysaccharide was dose-dependent,and there were no significant differences in these indexes between thymosin group and astragalus polysaccharide medium dose group(P>0.05).Conclusion:Astragalus polysaccharides can improve the liver function of mice with viral hepatitis,reduce the inflammatory response and pathological changes of liver tissue,reduce the level of virus,specu-late and inhibit NOD1/RIP2/NF-κB pathway and down-regulate NOD1,RIP2 and NF-κB p65 expressions,inhibit p-NF-κB p65 level,and high dose of astragalus polysaccharide has the best effect,which is better than thymosin-α1.
陈辰;胡丽霞
武汉市第一医院,武汉 430000
临床医学
黄芪多糖核苷酸结合寡聚化结构域1受体相互作用蛋白2核转录因子-κB免疫炎症病毒性肝炎肝损伤
Astragalus polysaccharideNucleotide-binding oligomerization domain 1Receptor-interacting protein 2Nuclear factor-κBImmunity inflammationViral hepatitisLiver injury
《中国免疫学杂志》 2024 (003)
556-563 / 8
评论